OliX Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dong-Ki Lee

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	23.6%
Management average tenure	no data
Board average tenure	4.1yrs

Recent management updates

Recent updates

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17

CEO

Dong-Ki Lee (51 yo)

no data

Tenure

Mr. Dong-Ki Lee Ph D., serves as Chief Executive Officer and Director at OliX Pharmaceuticals, Inc and was CSO until March 2021. Mr. Lee is a Professor of Global Research Laboratory(GRL) for RNAi Medicine...

Board Members

Name	Position	Tenure	Compensation	Ownership
Dong-Ki Lee	CEO & Director	no data	no data	23.63% ₩ 60.1b
Jong-Nam Seo	Director	no data	no data	no data
Aaron Hakim	Member of Scientific Advisory Board	4.1yrs	no data	no data
Sun-Woo Hong	Director	no data	no data	0.38% ₩ 960.2m
John Lis	Member of Scientific Advisory Board	no data	no data	no data
Sung-Hwa Hong	Director	no data	no data	no data
Demetrios Vavvas	Member of Science & Technology Advisory Board	5.1yrs	no data	no data
Hyewon Chung	Member of Scientific Advisory Board	5.3yrs	no data	no data
Yury Popov	Member of Scientific Advisory Board	4.1yrs	no data	no data
Gordon Jiang	Member of Scientific Advisory Board	4.1yrs	no data	no data
Tae-Gyeong Kim	Independent Outside Director	no data	no data	0.00061% ₩ 1.6m

4.1yrs

Average Tenure

52.5yo

Average Age

Experienced Board: A226950's board of directors are considered experienced (4.1 years average tenure).

OliX Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

No independent directors

No independent directors

Recent updates

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors

Full year 2023 earnings released: ₩1,324 loss per share (vs ₩1,877 loss in FY 2022)

OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Third quarter 2023 earnings released: ₩346 loss per share (vs ₩385 loss in 3Q 2022)

New minor risk - Shareholder dilution

OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia

OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment

Full year 2022 earnings released: ₩1,877 loss per share (vs ₩2,088 loss in FY 2021)

Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss

No independent directors

OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

Olix Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Olx101a in Patients with Hypertrophic Scars

OliX Pharmaceuticals, Inc announced that it has received KRW 57 billion in funding from a group of investors

OliX Pharmaceuticals, Inc announced that it expects to receive KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd. and other investors

Olix Pharmaceuticals,Inc Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics

No independent directors

OliX Pharmaceuticals,Inc Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate

OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Full year 2020 earnings released: ₩1,474 loss per share (vs ₩1,102 loss in FY 2019)

New 90-day low: ₩38,800

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

OliX Pharmaceuticals, Inc. Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

New 90-day high: ₩58,500

Third quarter 2020 earnings released: ₩639 loss per share

New 90-day high: ₩77,000

OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars

OliX Pharmaceuticals, Inc. Announces Expansion of Collaboration with Laboratoires Théa to Develop SiRNA Therapeutics for Ophthalmic Diseases

New 90-day high: ₩64,100

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

New 90-day high - ₩58,600

First half earnings released

New 90-day high - ₩53,700

CEO

Tenure

Board Members

Average Tenure

Average Age